Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.
A 19-year-old male with a family history of balding is using finasteride to thicken his hair and is considering whether to add minoxidil. Users suggest continuing finasteride for several months before deciding on minoxidil.
A 19-year-old shares their 6-month hair loss treatment results using finasteride, minoxidil, tretinoin, dermastamp, and azelaic acid, seeking advice for enhanced results. The conversation includes discussions on the availability of tretinoin.
The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
A user shared progress pictures after 5 months of using finasteride, noting hair growth and minimal side effects. They suggested adding minoxidil for further hair growth if needed.
The conversation is about a 19-year-old female experiencing hair loss, potentially due to deficiencies in iron, ferritin, and vitamin D. She is considering iron and vitamin D supplementation and exploring dietary changes, while also planning to consult a dermatologist when possible.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
A 19-year-old female with Diffuse Alopecia was advised by a dermatologist to use vitamin supplements, a hair serum, and antifungal drops, leading to some improvement. Other users suggested treatments like minoxidil, microneedling, and consulting a different dermatologist for further advice.
A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.
A 19-year-old is experiencing hair loss and considering treatments like finasteride, oral minoxidil, and possibly dutasteride. Users suggest continuing with finasteride and minoxidil, with some recommending dutasteride for stronger results.
A 25-year-old male experiencing diffuse thinning is advised to address high TSH levels and low iron, and consider treatments like finasteride. Weight loss and improved diet are also suggested to potentially help with hair health.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.
An 18/19-year-old male started balding at 16 and initially saw hair growth with minoxidil, but results diminished over time. He switched dermatologists and is now using a regimen of topical finasteride, minoxidil, vitamin D, and supplements, hoping for better results.
Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.
A user observed orange fluorescence on their nose and hair under a black light, indicating Cutibacterium acnes, which may contribute to hair loss alongside androgenic alopecia. A suggestion was made to use coal tar shampoo to address the issue.
A 19-year-old is struggling with hair loss despite using minoxidil and finasteride, feeling depressed and lacking confidence. Suggestions include trying dutasteride, topical treatments, hair transplants, or accepting baldness.
A 19-year-old shared their positive results after 9 months using topical minoxidil and dutasteride for hair loss. They started with twice-daily minoxidil applications, later reducing to once daily, and took 0.5mg of dutasteride.
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.
A 19-year-old is using oral dutasteride, topical minoxidil, and dermastamping to address hair loss and enhance facial hair growth, experiencing minimal side effects and increased body hair. They report positive results in hairline thickness and temple closure.
A person with alopecia universalis is considering using Xeljanz but is advised that Olumiant is more effective for their condition. They are under a dermatologist's care and should expect gradual progress, as follicles dormant for 20 years are challenging to reactivate.
A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.
The user is considering blood tests to understand their receding hairline and is exploring brewer's yeast for its biotin content. They have been using topical Minoxidil, biotin, collagen, and microneedling, but are avoiding oral Finasteride and Dutasteride.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.